At the news
? BEARISHIMPACT 6/10 PRESS-RELEASE filed Aug 19, 2026 at 08:26 ET
Chemomab Therapeutics reported Q1 2026 EPS of -$0.24, a 51.8% miss vs consensus of $0.00, with no revenue. The planned merger with Scipher Medicine to advance nebokitug into a Phase 2 RA trial is progressing, with closing expected by year-end. The significant EPS miss and lack of revenue highlight the pre-revenue clinical-stage nature of the company, but the merger catalyst provides a potential value inflection point.
- Q1 2026 EPS of -$0.24 missed consensus of $0.00 by 51.8%
- No revenue reported for the quarter
- Planned merger with Scipher Medicine to assess nebokitug in Phase 2 RA trial continues, closing expected by year-end
- Market cap of $14M with 88% analyst bullish rating
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access